Respiratory medicine
-
Respiratory medicine · Sep 2010
Randomized Controlled TrialTolerability and efficacy of inhaled AZD4818, a CCR1 antagonist, in moderate to severe COPD patients.
This study evaluated the tolerability and efficacy of inhaled AZD4818, a CCR1 antagonist, in patients with COPD. ⋯ Inhaled AZD4818 was well tolerated at 300mug twice daily for 4 weeks in patients with COPD; however, there was no indication of a beneficial treatment effect despite exposure as expected. These findings in COPD are in line with other studies reporting a lack of clinical efficacy with CCR1 antagonists in other therapy areas.